The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.
about
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose.Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc.Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).Gut hormones: the future of obesity treatment?Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.Effects of glucagon-like peptide-1 receptor agonists on renal functionObesity and type 2 diabetes: which patients are at risk?Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?Exenatide extended-release: a review of its use in type 2 diabetes mellitus.One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.Sericin protects against diabetes-induced injuries in sciatic nerve and related nerve cells.The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial.Ultra-high-performance liquid chromatography for the determination of exenatide in monkey plasma by tandem quadrupole mass spectrometry.Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.
P2860
Q33960291-8A28C7DC-E4CC-4EEB-B426-6729BE23A411Q34503796-7F741F17-BB92-46B1-A7B6-9304B00EC9C8Q35690970-84151743-84D9-4379-AE52-E5955312DCFFQ35976515-32FB10B8-18FF-41E4-B2EC-46DF45A685A0Q36032335-C25F4907-1C69-4CE0-B646-28754E67D3DFQ36303786-C7B5DC89-3D42-4745-B903-AF2AD4C351C9Q36468102-6E718C09-4F3C-4328-9BC7-48C418135D9DQ36498695-C9B61D8A-60A6-427D-BB56-D68E548DF45CQ37232679-991341D6-A936-4419-8C75-AB31E8C833CEQ37954693-4813038F-BA31-46A7-B411-BEFF7C4F5C9EQ38005223-791EDE46-5384-4502-8320-6044A577D206Q38032321-3469C194-CC0A-44EB-925F-B4C52E50ACB4Q41604037-8A7609E9-1BBB-4823-A156-E912A9CADCA7Q41890065-349EF0D0-8AF4-4517-950A-054AAAE6CDD9Q42130324-55C4019D-4E79-4B9D-A40F-E41FF7A814BCQ48122512-981E9BEB-C9D4-430E-BADE-4632CCCF3D60Q49474845-2A1B5876-0DC6-475D-900B-03A102C7109BQ51325474-68723E41-E024-4808-9F00-428BEC626D0DQ51381364-00C0D3B6-D758-4F1D-BD40-7CB56ADBDC0D
P2860
The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The safety and tolerability of ...... treatment of type-2 diabetes.
@en
The safety and tolerability of ...... treatment of type-2 diabetes.
@nl
type
label
The safety and tolerability of ...... treatment of type-2 diabetes.
@en
The safety and tolerability of ...... treatment of type-2 diabetes.
@nl
prefLabel
The safety and tolerability of ...... treatment of type-2 diabetes.
@en
The safety and tolerability of ...... treatment of type-2 diabetes.
@nl
P2860
P1476
The safety and tolerability of ...... treatment of type-2 diabetes.
@en
P2093
D Russell-Jones
P2860
P304
P356
10.1111/J.1742-1241.2010.02465.X
P577
2010-09-01T00:00:00Z